A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors

A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of AST-001 administered as a single agent.

Trial Details

NCT ID
NCT06245330
Phase
PHASE1 / PHASE2
Sponsor
Ascentawits Pharmaceuticals, Ltd
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • AST-001
Locations (sample)
  • Changchun, Jinlin, China|43.88,125.32278

Key Eligibility Criteria

  • Patient has ability to understand the risks of the study and is willing to comply with the protocol and has signed a written informed consent.
  • Aged 18-70 years (inclusive), males and females.
  • Histologically or cytologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative do not exist or are n…
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →